Display options
Cite
Yates A, Norwig J, Maroon JC, et al. Evaluation of lipid profiles and the use of omega-3 essential Fatty Acid in professional football players. Sports Health. 2009;1(1):21-30doi: 10.1177/1941738108326978.
Yates, A., Norwig, J., Maroon, J. C., Bost, J., Bradley, J. P., Duca, M., Wecht, D. A., Grove, R., Iso, A., Cobb, I., Ross, N., & Borden, M. (2009). Evaluation of lipid profiles and the use of omega-3 essential Fatty Acid in professional football players. Sports health, 1(1), 21-30. https://doi.org/10.1177/1941738108326978
Yates, Anthony, et al. "Evaluation of lipid profiles and the use of omega-3 essential Fatty Acid in professional football players." Sports health vol. 1,1 (2009): 21-30. doi: https://doi.org/10.1177/1941738108326978
Yates A, Norwig J, Maroon JC, Bost J, Bradley JP, Duca M, Wecht DA, Grove R, Iso A, Cobb I, Ross N, Borden M. Evaluation of lipid profiles and the use of omega-3 essential Fatty Acid in professional football players. Sports Health. 2009 Jan;1(1):21-30. doi: 10.1177/1941738108326978. PMID: 23015851; PMCID: PMC3445114.
Copy Download .nbib Format: NLM
Share it on

Sports Health. 2009 Jan;1(1):21-30. doi: 10.1177/1941738108326978.

Evaluation of lipid profiles and the use of omega-3 essential Fatty Acid in professional football players.

Sports health

Anthony Yates, John Norwig, Joseph C Maroon, Jeffrey Bost, James P Bradley, Mark Duca, Daniel A Wecht, Ryan Grove, Ariko Iso, Ingrid Cobb, Nathan Ross, Meghan Borden

Affiliations

  1. University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

PMID: 23015851 PMCID: PMC3445114 DOI: 10.1177/1941738108326978

Abstract

BACKGROUND: Recent research showed 82% of 233 retired National Football League players under age 50 had abnormal narrowing and blockages in arteries compared to the general population of the same age. It has been suggested that early screening and intervention in this at-risk population be a priority.

HYPOTHESIS: Omega-3 essential fatty acid has been shown to improve cardiovascular lipid risk factors and should improve lipid profiles in professional football players to help reduce their recently shown accelerated risk of developing cardiovascular disease.

METHODS: A total of 36 active national football players were randomly assigned to 2 groups: the first group (n = 20) was provided fish oil capsules (2200 mg of mixed docosahexaenoic acid and eicosapentaenoic acid and 360 mg of other omega-3s), and the second group (n = 16) served as controls during a 60-day trial. Vertical Auto Profile cholesterol tests directly measuring serum low-density lipoprotein, high-density lipoprotein, and other subfractions were performed. Compliance, side effects, and seafood consumption data were also collected. Baseline, midpoint, and poststudy blood work measured plasma docosahexaenoic acid and eicosapentaenoic acid.

RESULTS: Treatment increased high-density lipoprotein (average percent change: +25.96, control +14.16), decreased triglycerides treatment (-8.06, control +43.98), very low-density lipoprotein treatment (-13.98, control +23.18), intermediate density lipoprotein (-27.58, control +12.07), remnant lipoproteins (-23.86, control +8.33), and very low-density lipoprotein-3 (-17.10, control +7.77). An average increase of 106.67% for docosahexaenoic acid and 365.82% for eicosapentaenoic acid compared to control was also shown.

CONCLUSION: Omega-3 supplementation significantly improved the lipid profile of active players randomized to treatment. These results suggest that fish oil supplementation is an effective way to increase eicosapentaenoic acid and docosahexaenoic acid levels in plasma and should be considered as a method to improve modifiable cardiovascular risk lipid factors in professional football players.

CLINICAL RELEVANCE: A prospective study examining the effects of 60 days of a highly purified fish oil supplementation in professional football players.

Keywords: cardiac risk factors; omega-3; professional football; vertical auto profile cholesterol test

References

  1. Circulation. 2004 Jun 8;109(22):2807-16 - PubMed
  2. Circulation. 2000 Oct 17;102(16):1886-92 - PubMed
  3. N Engl J Med. 2003 Sep 11;349(11):1064-75 - PubMed
  4. Lipids. 2003 Apr;38(4):353-8 - PubMed
  5. Atherosclerosis. 2000 Feb;148(2):387-96 - PubMed
  6. Lancet. 2002 Jul 6;360(9326):7-22 - PubMed
  7. Med Sci Sports Exerc. 2007 Jun;39(6):903-9 - PubMed
  8. Circulation. 1996 Nov 1;94(9):2337-40 - PubMed
  9. Diabetes Care. 2007 Jan;30(1):144-6 - PubMed
  10. Ann Epidemiol. 1992 Jan-Mar;2(1-2):23-8 - PubMed
  11. Prev Med. 2004 Jul;39(1):212-20 - PubMed
  12. J Nucl Med. 2007 Nov;48(11):1800-15 - PubMed
  13. Arterioscler Thromb Vasc Biol. 1998 Apr;18(4):577-83 - PubMed
  14. J Nutr. 1996 Apr;126(4 Suppl):1053S-7S - PubMed
  15. Adv Intern Med. 1990;35:139-71 - PubMed
  16. Am J Cardiol. 2006 Aug 21;98(4A):50i-60i - PubMed
  17. J Nutr. 2003 Nov;133(11):3643-50 - PubMed
  18. Mayo Clin Proc. 2003 Aug;78(8):965-78 - PubMed
  19. Atherosclerosis. 1996 Jul;124 Suppl:S1-9 - PubMed
  20. JAMA. 1995 Nov 1;274(17):1363-7 - PubMed
  21. Atherosclerosis. 1996 Sep 6;125(2):231-42 - PubMed
  22. Am J Cardiol. 2001 Jan 1;87(1):44-8 - PubMed
  23. J Cardiovasc Risk. 1996 Apr;3(2):213-9 - PubMed
  24. Circulation. 1999 Sep 28;100(13):1481-92 - PubMed
  25. Am J Med. 2002 Mar;112(4):298-304 - PubMed
  26. Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15184-9 - PubMed
  27. Circulation. 1993 Nov;88(5 Pt 1):2180-9 - PubMed
  28. Circulation. 1990 Aug;82(2):495-506 - PubMed
  29. Circulation. 2004 Jun 15;109(23 Suppl 1):III50-7 - PubMed
  30. JAMA. 1996 Sep 18;276(11):882-8 - PubMed
  31. Lancet. 1999 Aug 7;354(9177):447-55 - PubMed
  32. Recent Pat Cardiovasc Drug Discov. 2007 Jan;2(1):13-21 - PubMed
  33. Circulation. 1998 Mar 24;97(11):1029-36 - PubMed
  34. Circulation. 2005 Nov 15;112(20):3184-209 - PubMed
  35. Circulation. 2002 Nov 19;106(21):2747-57 - PubMed
  36. Exerc Sport Sci Rev. 1994;22:477-521 - PubMed
  37. Arterioscler Thromb. 1992 Feb;12(2):187-95 - PubMed
  38. N Engl J Med. 2001 Nov 29;345(22):1583-92 - PubMed
  39. JAMA. 2001 May 16;285(19):2486-97 - PubMed
  40. Arterioscler Thromb Vasc Biol. 1996 May;16(5):697-704 - PubMed
  41. Arterioscler Thromb Vasc Biol. 2003 Feb 1;23(2):153-5 - PubMed
  42. J Lab Clin Med. 2003 Jan;141(1):41-9 - PubMed
  43. Front Biosci. 2001 Mar 01;6:D366-87 - PubMed
  44. Ann N Y Acad Sci. 2002 Jun;967:329-35 - PubMed
  45. Arterioscler Thromb Vasc Biol. 2000 Aug;20(8):1990-7 - PubMed
  46. Curr Opin Lipidol. 1994 Dec;5(6):395-403 - PubMed
  47. Am J Clin Nutr. 2007 May;85(5):1267-74 - PubMed
  48. Atherosclerosis. 1994 Apr;106(2):241-53 - PubMed
  49. Clin Chem. 2002 Feb;48(2):217-9 - PubMed
  50. Diabetes Care. 1998 May;21(5):717-24 - PubMed
  51. N Engl J Med. 1988 Mar 3;318(9):549-57 - PubMed
  52. Metabolism. 2004 Jun;53(6):749-54 - PubMed

Publication Types